700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Review Article Open Access
Tumor-associated RAC1b overexpression has been recently highlighted as one promising target for therapeutic intervention in pancreatic, breast, colon and lung cancer. Recent data documenting RAC1b overexpression in a subset of papillary thyroid carcinomas, carrying the activating mutation BRAFV600E and associated with an unfavorable outcome, support the inclusion of thyroid cancer to the previous list thus opening new therapeutic avenues to thyroid cancer patients.
Herein, we will focus on the potential of RAC1b, a hyperactive variant of the small GTPase RAC1, as a molecular player in the development of thyroid malignancies.
Thyroid cancer, Rac1b, Rac1 splice variant, Clinical outcome, Molecular marker, Cancer Progression and Diagnostics,Molecular Diagnostics